Related Experiment Videos
[Clinical study on chanlibao in accelerating second stage of labor]
1Department of Obstetrics and Gynecology, Xiehe Hospital, Tongji Medical University, Wuhan 430022.
Summary
Chanlibao (CLB), a Chinese herbal medicine, effectively strengthens uterine contractions and shortens labor duration. This safe and cost-effective treatment improves outcomes for mothers and newborns, offering an alternative to oxytocin.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Traditional Chinese Medicine
Background:
- Uterine contractions are crucial for labor progression.
- Oxytocin is commonly used to augment labor but carries risks.
- A need exists for safe and effective labor-augmenting agents.
Purpose of the Study:
- To evaluate Chanlibao (CLB) as a novel agent to enhance uterine contractions.
- To determine if CLB can shorten the second stage of labor.
- To assess the safety and efficacy of CLB for improving maternal and neonatal outcomes.
Main Methods:
- A randomized controlled trial involving primiparae.
- Three groups: CLB (n=80), oxytocin (OTC, n=52), and control (n=29).
- Monitoring of labor duration, intrauterine pressure, fetal heart rate, and maternal/neonatal prognosis.
Main Results:
- CLB significantly reduced the time of the second stage of labor (TSL) and postpartum hemorrhage compared to the control group.
- Increased intrauterine pressure was observed with CLB, comparable to oxytocin.
- No adverse side effects were reported for CLB.
Conclusions:
- CLB is a safe, effective, and affordable option for strengthening uterine contractions and shortening labor.
- CLB offers a beneficial alternative to oxytocin, particularly for patients where oxytocin is contraindicated.
- The use of CLB can improve the prognosis for both mothers and newborns.